In this episode,  an international expert panel shares their thoughts on what will be needed from future long-acting HIV treatment and prevention strategies to address populations who are not eligible for currently available long-acting options. The faculty members also discuss important considerations for leveraging long-acting HIV approaches to address care inequities across different populations.Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; essential considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection, such as the role of the lead-in phase, new guideline recommendations for monitoring during PrEP, and patient care and follow-up after PrEP discontinuation; and important considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium.Presenters:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisYvonne Gilleece, MB BCh, BAOHonorary Clinical Professor in HIV Medicine and Sexual HealthDepartment of Global Health & HIVBrighton & Sussex Medical SchoolConsultant in HIV Medicine and Sexual HealthHIV DepartmentUniversity Hospitals Sussex NHS Foundation TrustBrighton, United Kingdom Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyDarrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program: https://bit.ly/3P3uPBc